Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

Rhea-AI Summary

Revelation Biosciences Inc. (NASDAQ: REVB) will present a corporate overview at the BIO CEO & Investor Conference on February 14, 2022, at 10:45 a.m. EST in New York City. CEO James Rolke will host one-on-one meetings throughout the event. The company is focused on developing immunologic therapies, including REVTx-99 for respiratory virus infections and REVTx-200 for enhanced vaccination immunity. Revelation is also advancing REVDx-501, a rapid home diagnostic for respiratory viruses. For details, visit RevBiosciences.com.

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at 10:45 a.m. EST on February 14, 2022 at the BIO CEO & Investor Conference, which is being held at the New York Marriott Marquis in New York City, NY on February 14-17.

Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

For more information on Revelation, please visit www.RevBiosciences.com.

Company Contacts

Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com

and

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

 

FAQ

What is the date and time of Revelation Biosciences' presentation at the BIO CEO & Investor Conference?

Revelation Biosciences will present on February 14, 2022, at 10:45 a.m. EST.

Where is the BIO CEO & Investor Conference being held?

The conference is at the New York Marriott Marquis in New York City.

Who is the CEO presenting at the conference for Revelation Biosciences?

James Rolke is the CEO presenting at the conference.

What are the key products being developed by Revelation Biosciences?

Revelation is developing REVTx-99, REVTx-200, and REVDx-501.

What is REVTx-99 used for?

REVTx-99 is an intranasal immunomodulator for preventing and treating infections from respiratory viruses.

What type of company is Revelation Biosciences?

Revelation Biosciences is a clinical-stage life sciences company.